Keryx Biopharma revenues up 50% in Q3

• Keryx Biopharmaceuticals (NASDAQ:KERX +5.3%) Q3 results: Revenues: $6.3M (+50.0%); Operating Loss: ($41.8M) (-35.7%); Net Loss: ($41.7M) (-35.8%); Loss Per Share: ($0.39) (-34.5%); Quick Assets: $132.2M (-34.0%).
• No guidance given.